Cohance Lifesciences Limited
DSP Mutual Fund reduced its stake in Cohance Lifesciences from 4.29% to 3.53% by selling 28,99,996 shares in an open market transaction on August 7, 2026.
A Hyderabad-based contract development and manufacturing organization serving leading global pharmaceutical and fine chemical companies. Cohance Life provides integrated services spanning process research and development through late-stage clinical and commercial manufacturing for new chemical entities. The company distinguishes itself through its commitment to delivering customized solutions that fulfill specific customer needs and expectations across the entire drug development lifecycle.
Standalone AMC after DSP Group acquired full ownership from BlackRock in 2018. Manages over Rs 1.9 lakh crore. Known for equity funds with a clear process-first culture and minimal star manager dependency. CEO Kalpen Parekh is widely respected for transparent investor communication. DSP Small Cap Fund and DSP Midcap Fund are flagship offerings.